



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Camrelizumab

Cat. No.:	HY-P9971
CAS No.:	1798286-48-2
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Camrelizumab (SHR-1210) is a potent humanized high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC ₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al ^{[1][2]} .
IC₅₀ & Target	IC ₅₀ : 0.70 nM (PD-1/PD-L1 interaction) ^[1]
In Vitro	In a T cell proliferation assay using tuberculin treated peripheral blood mononuclear cells, Camrelizumab induces a T cell proliferation at an EC ₅₀ of 0.11 nM. In a similar assay measuring IFN-gamma secretion, Camrelizumab induces IFN-gamma production at an EC ₅₀ of 0.38 nM ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Camrelizumab (3 mg/kg) combines with apatinib (200 and 100 mg/kg) inhibits the tumor inhibition rates reached 63.1% and 87.3%, respectively in human PD-1 transgenic mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Front Oncol. 2022 Jul 28;12:960066.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Kuimin Mei, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021 Mar;9(3):e002191.
- [2]. Jason D Lickliter, et al. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther
- [3]. Caicun Zho, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA